Investors Alert: Kyverna Therapeutics Faces Securities Class Action Lawsuit
Kyverna Therapeutics faces a securities class action lawsuit filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors. The complaint alleges false statements regarding clinical trial data. Investors can seek lead plaintiff representation until February 7, 2025.
This news matters as it highlights potential misconduct by Kyverna Therapeutics, Inc. and the opportunity for affected investors to seek legal recourse. Investors who purchased Kyverna stock during the IPO period should take note of the lead plaintiff deadline and consider their options for potential recovery.
